ProCE Banner Activity

Correlation of Survival and Other Clinical Benefits With Imetelstat Therapy in High-Risk, JAK Inhibitor–Refractory Myelofibrosis

Slideset Download
Conference Coverage
Imetelstat, a telomerase inhibitor, shows dose-dependent improvements in OS and trends in correlation with other clinical benefits in patients with JAK inhibitor–refractory, high-risk myelofibrosis.

Released: December 10, 2020

Expiration: December 09, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology